SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin-Reference-Cited by-同舟云学术

SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin

Published:2021-11-29 Issue: Volume: Page:
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Volk Andreas,Covini-Souris Caroline,Kuehnel Denis,De Mey Christian,Römisch Jürgen,Schmidt Torben

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-021-00511-9.pdf

Reference59 articles.

1. Nobel Media AB 2021. The Nobel Prize in Physiology or Medicine 1901. 1901. https://www.nobelprize.org/prizes/medicine/1901/summary/. Accessed 6 Jun 2021.

2. Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59: 102790. https://doi.org/10.1016/j.transci.2020.102790.

3. Focosi D, Tuccori M, Franchini M. The road towards polyclonal anti-SARS-CoV-2 immunoglobulins (Hyperimmune Serum) for passive immunization in COVID-19. Life (Basel). 2021. https://doi.org/10.3390/life11020144.

4. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398–400. https://doi.org/10.1016/S1473-3099(20)30141-9.

5. Food and Drug Administration. Emergency Use Authorization of Covid-19 convalescent plasma.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment;Vaccine;2024-11

2. An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity;Vaccines;2024-06-18

3. Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report;Frontiers in Immunology;2024-04-19

4. The impact of COVID-19 infection in pediatric and adult patients with primary immunodeficiency: a single center analysis;LymphoSign Journal;2024-01-11

5. Vaccination against respiratory tract pathogens in primary immune deficiency patients receiving immunoglobulin replacement therapy;TUBERK TORAK;2024